2589 Stock Overview
Realcan Pharmaceutical Group Co., Ltd. sells medicines, medical devices, and medical consumables to medical institution worldwide.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 1/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Realcan Pharmaceutical Group Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥2.68 |
52 Week High | CN¥3.96 |
52 Week Low | CN¥2.05 |
Beta | 0.54 |
1 Month Change | -8.84% |
3 Month Change | 19.64% |
1 Year Change | -28.91% |
3 Year Change | -37.53% |
5 Year Change | -64.88% |
Change since IPO | 0.88% |
Recent News & Updates
Recent updates
Shareholder Returns
2589 | CN Healthcare | CN Market | |
---|---|---|---|
7D | 6.3% | 1.3% | 1.2% |
1Y | -28.9% | -31.9% | -12.6% |
Return vs Industry: 002589 exceeded the CN Healthcare industry which returned -31.9% over the past year.
Return vs Market: 002589 underperformed the CN Market which returned -12.6% over the past year.
Price Volatility
2589 volatility | |
---|---|
2589 Average Weekly Movement | 7.9% |
Healthcare Industry Average Movement | 6.6% |
Market Average Movement | 8.3% |
10% most volatile stocks in CN Market | 12.1% |
10% least volatile stocks in CN Market | 5.0% |
Stable Share Price: 002589 has not had significant price volatility in the past 3 months.
Volatility Over Time: 002589's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2004 | 5,118 | Renhua Zhang | www.realcan.cn |
Realcan Pharmaceutical Group Co., Ltd. sells medicines, medical devices, and medical consumables to medical institution worldwide. The company operates in Drug and Equipment Distribution, Medical Diagnosis, Academic Service, Digital Medical, Pharmaceutical Logistics, and Traditional Chinese Medicine segments. It sells drugs and medical devices.
Realcan Pharmaceutical Group Co., Ltd. Fundamentals Summary
2589 fundamental statistics | |
---|---|
Market cap | CN¥4.03b |
Earnings (TTM) | CN¥14.33m |
Revenue (TTM) | CN¥7.98b |
281.5x
P/E Ratio0.5x
P/S RatioIs 2589 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2589 income statement (TTM) | |
---|---|
Revenue | CN¥7.98b |
Cost of Revenue | CN¥7.23b |
Gross Profit | CN¥750.53m |
Other Expenses | CN¥736.21m |
Earnings | CN¥14.33m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.0095 |
Gross Margin | 9.41% |
Net Profit Margin | 0.18% |
Debt/Equity Ratio | 89.8% |
How did 2589 perform over the long term?
See historical performance and comparison